Tenderwize
Wróć do wyszukiwania

Non-exclusive drug discount agreement for Vilanterol/Fluticasone

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2028 · 582 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Vilanterol/Fluticason (ATC-Code nach WHO: R03AK10)

60/100

Ocena szansy

PromisingLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

15 / 100

Czynniki ryzyka

No guaranteed minimum purchase; actual revenue is uncertain and may be low.

The Open-House procedure may be terminated early if exclusive agreements are concluded, ending existing discount agreem...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Supply of pharmaceutical products containing Vilanterol/Fluticasone (ATC R03AK10) under a non-exclusive discount agreement.
  • The agreement is open to all interested pharmaceutical companies that meet the participation requirements.
Pokaż pełne podsumowanie

This is a non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active substance Vilanterol/Fluticasone (ATC R03AK10) via an Open-House model. The contracting authority is AOK PLUS, covering Saxony and Thuringia. The procedure is not a classic public procurement but a voluntary transparency publication. No estimated value, no guaranteed purchase quantities, and no exclusivity. The agreement ends 31 March 2028. Submission via DTVP portal; first deadline 5 March 2026.

Ryzyka

No guaranteed minimum purchase; actual revenue is uncertain and may be low.

The Open-House procedure may be terminated early if exclusive agreements are concluded, ending existing discount agreem...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal products.

Eligibility

  • Must submit a declaration of no conflict of interest (exclusion grounds per §§ 123, 124 GWB).

Administrative

  • Must submit a declaration regarding Russia sanctions (EU Regulation 833/2014).

Kryteria udzielenia

Lot 1

No explicit award criteria provided; the agreement is based on acceptance of predetermined discount terms.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive drug discount agreement for Vilanterol/Fluticasone

Open-House model for non-exclusive discount agreements on pharmaceuticals containing Vilanterol/Fluticasone (ATC R03AK10). No exclusivity, no guaranteed minimum purchase. The agreement term ends 31 March 2028. Participation requires acceptance of the discount terms and confidentiality obligations.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Mar 2026 - Mar 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

No explicit award criteria provided; the agreement is based on acceptance of predetermined discount terms.

Termin

Expired Mar 05, 2026

Szczegóły zamówienia

Data publikacji
15 Jan 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
32969-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3